Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stevo Julius

Showing results (11-20 of 118) with videos related to

Pageof 12
Sort By:
Current Hypertension Reports|May 16, 2009
The role of cardiac autonomic function in hypertension and cardiovascular diseasePaolo Palatini, Stevo Julius
American Heart Journal|November 4, 2004
Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockersSverre E Kjeldsen, Stevo Julius
Current Hypertension Reports|September 9, 2008
Prehypertension: risk stratification and management considerationsBrent M Egan, Stevo Julius
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|August 20, 2002
AT1 blockers: are there alternative pathways reducing cardiovascular risk? IntroductionPeter A van Zwieten, Stevo Julius
Drugs|February 3, 2006
Impact of increased heart rate on clinical outcomes in hypertension: implications for antihypertensive drug therapyPaolo Palatini, Athanase Benetos, Stevo Julius
Journal of Hypertension|July 16, 2008
Office and out of office heart rate measurements: which clinical value?Paolo Palatini, Gianfranco Parati, Stevo Julius
Journal of Hypertension|September 1, 2016
ReplyPaolo Palatini, Stevo Julius, Alberto Zanchetti
Journal of Clinical Hypertension (Greenwich, Conn.)|April 5, 2013
Reply to Visit-to-visit blood pressure variation: time to reanalyze all the data from the TROPHY studyStevo Julius, Niko Kaciroti, Suzanne Oparil
Circulation|May 21, 2008
Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertensionFranz H Messerli, Sripal Bangalore, Stevo Julius
American Journal of Hypertension|February 28, 2007
From TROPHY with prideStevo Julius, Anthony Schork, Brent M Egan
Pageof 12

Showing results (11-20 of 118) with videos related to

Sort By:
Pageof 12
Current Hypertension Reports|May 16, 2009
The role of cardiac autonomic function in hypertension and cardiovascular diseasePaolo Palatini, Stevo Julius
American Heart Journal|November 4, 2004
Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockersSverre E Kjeldsen, Stevo Julius
Current Hypertension Reports|September 9, 2008
Prehypertension: risk stratification and management considerationsBrent M Egan, Stevo Julius
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|August 20, 2002
AT1 blockers: are there alternative pathways reducing cardiovascular risk? IntroductionPeter A van Zwieten, Stevo Julius
Drugs|February 3, 2006
Impact of increased heart rate on clinical outcomes in hypertension: implications for antihypertensive drug therapyPaolo Palatini, Athanase Benetos, Stevo Julius
Journal of Hypertension|July 16, 2008
Office and out of office heart rate measurements: which clinical value?Paolo Palatini, Gianfranco Parati, Stevo Julius
Journal of Hypertension|September 1, 2016
ReplyPaolo Palatini, Stevo Julius, Alberto Zanchetti
Journal of Clinical Hypertension (Greenwich, Conn.)|April 5, 2013
Reply to Visit-to-visit blood pressure variation: time to reanalyze all the data from the TROPHY studyStevo Julius, Niko Kaciroti, Suzanne Oparil
Circulation|May 21, 2008
Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertensionFranz H Messerli, Sripal Bangalore, Stevo Julius
American Journal of Hypertension|February 28, 2007
From TROPHY with prideStevo Julius, Anthony Schork, Brent M Egan
Pageof 12